Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT ID: NCT00228605

Last Updated: 2014-05-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain Migraine Diabetic Neuropathies Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OraVescent Fentanyl

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic pain diagnosis
* Opioid tolerant
* Has on average 1-4 breakthrough pain episodes per day

Exclusion Criteria

* Drug abuse history
* Cardiopulmonary disease
* Monoamine oxidase inhibitors (MAOIs)
* Expected to have surgery to relieve the pain
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cephalon

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gwendolyn Neibler, DO

Role: STUDY_DIRECTOR

Cephalon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MedSearch

Calera, Alabama, United States

Site Status

Clinical Research Consultants, Inc.

Hoover, Alabama, United States

Site Status

Arizona Research Center

Phoenix, Arizona, United States

Site Status

NEA Clinic

Jonesboro, Arkansas, United States

Site Status

Lynn Institute of the Rockies

Colorado Springs, Colorado, United States

Site Status

Radiant Research-Daytona Beach

Daytona Beach, Florida, United States

Site Status

Advent Clinical Research Centers, Inc.

St. Petersburg, Florida, United States

Site Status

Gold Coast Research

Weston, Florida, United States

Site Status

Center for Prospective Outcome Studies, Inc.

Atlanta, Georgia, United States

Site Status

Advent Clinical Research Centers, Inc.

Atlanta, Georgia, United States

Site Status

Center for Prospective Outcome Studies, Inc.

Marietta, Georgia, United States

Site Status

North Fulton Regional Hospital Pain Center

Roswell, Georgia, United States

Site Status

Carmen Research

Smyrna, Georgia, United States

Site Status

Orthopedic Health Care

Boise, Idaho, United States

Site Status

Medisphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Tri-State Arthritis & Rheumatology Center, LLC

Evansville, Indiana, United States

Site Status

Iowa Pain Management Clinic, PC

Des Moines, Iowa, United States

Site Status

Mid-America Physiatrists, PA

Overland Park, Kansas, United States

Site Status

Capital Clinical Research Associates, LLC

Rockville, Maryland, United States

Site Status

Brigham Women's Hospital, Attn: Pain Trials Center

Boston, Massachusetts, United States

Site Status

MedVadis Research

Wellesley Hills, Massachusetts, United States

Site Status

Medex Healthcare Research Center

St Louis, Missouri, United States

Site Status

Radiant Research - St. Louis

St Louis, Missouri, United States

Site Status

Clinical Research Center of Nevada

Las Vegas, Nevada, United States

Site Status

Northshore University Hospital

Bethpage, New York, United States

Site Status

NYU Pain Management Center

New York, New York, United States

Site Status

Research Across America

New York, New York, United States

Site Status

The Lynn Health Science Institute

Oklahoma City, Oklahoma, United States

Site Status

Southern Oregon Health & Wellness

Medford, Oregon, United States

Site Status

Clinical Research Center of Reading, LLP

West Reading, Pennsylvania, United States

Site Status

Healthstar Physicians

Morristown, Tennessee, United States

Site Status

Biopharma Research Associates

Sugar Land, Texas, United States

Site Status

Lifetree Clinical Research

Salt Lake City, Utah, United States

Site Status

Radiant Research

Salt Lake City, Utah, United States

Site Status

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Site Status

Pain Management Center

South Burlington, Vermont, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

Rowan Research

Spokane, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C25608/3040/BP/US

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety of Fentanyl TAIFUN Treatment
NCT00822614 UNKNOWN PHASE3
A Phase III Clinical Study of KW-2246
NCT00683995 COMPLETED PHASE3